Abstract
Heat Shock Protein 90 (HSP90) is a ubiquitous molecular chaperone that is considered to be the most abundantly expressed protein in various human cancers such as breast, lung, colon, prostate, leukemia and skin. The master regulator, HSP90 plays a pivotal role in the conformational stabilization, maturation and activity of its various labile oncogenic client proteins such as p53, ErbB2, Bcr-Abl, Akt, Her-2, Cdk4, Cdk6, Raf-1 and v-Src in altered cells. Hence, making a guaranteed attempt to inhibit such a master regulator for cancer therapy appears to be a potential approach for combinatorial inhibition of numerous oncogenic signaling pathways simultaneously. Considerable efforts are being under way to develop novel molecular targets and its inhibitors that may block key signaling pathways involved in the process of tumorigenesis and metastasis. In this regards, HSP90 has acquired immense interest as a potent anticancer drug-target due to its key functional link with multiple signaling pathways involved in the process of cell proliferation and cell survival. Notably, geldanamycin and its derivatives (17-AAG, 17-DMAG) have shown quite encouraging results in inhibiting HSP90 function in several cancers and currently almost 17 drug candidates known to be target HSP90 are being under clinical trials either as single agents or combinatorial therapy. Hence, this review is an attempt to get new insight into novel drug target therapy by focusing on recent advances made in understanding HSP90 chaperone structure-function relationships, identification of new HSP90 client proteins and, more importantly, on the advancements of HSP90 targeted therapy based on various existing and emerging classical inhibitors.
Keywords: Heat shock protein, HSP90, Cancer, Drug, 17-AAG, 17-DMG, IP104.
Current Pharmaceutical Design
Title:Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Volume: 22 Issue: 20
Author(s): Absarul Haque, Qamre Alam, Mohammad Zubair Alam, Esam I. Azhar, Khalid Hussain Wali Sait, Nisrin Anfinan, Gohar Mushtaq, Mohammad Amjad Kamal and Mahmood Rasool
Affiliation:
Keywords: Heat shock protein, HSP90, Cancer, Drug, 17-AAG, 17-DMG, IP104.
Abstract: Heat Shock Protein 90 (HSP90) is a ubiquitous molecular chaperone that is considered to be the most abundantly expressed protein in various human cancers such as breast, lung, colon, prostate, leukemia and skin. The master regulator, HSP90 plays a pivotal role in the conformational stabilization, maturation and activity of its various labile oncogenic client proteins such as p53, ErbB2, Bcr-Abl, Akt, Her-2, Cdk4, Cdk6, Raf-1 and v-Src in altered cells. Hence, making a guaranteed attempt to inhibit such a master regulator for cancer therapy appears to be a potential approach for combinatorial inhibition of numerous oncogenic signaling pathways simultaneously. Considerable efforts are being under way to develop novel molecular targets and its inhibitors that may block key signaling pathways involved in the process of tumorigenesis and metastasis. In this regards, HSP90 has acquired immense interest as a potent anticancer drug-target due to its key functional link with multiple signaling pathways involved in the process of cell proliferation and cell survival. Notably, geldanamycin and its derivatives (17-AAG, 17-DMAG) have shown quite encouraging results in inhibiting HSP90 function in several cancers and currently almost 17 drug candidates known to be target HSP90 are being under clinical trials either as single agents or combinatorial therapy. Hence, this review is an attempt to get new insight into novel drug target therapy by focusing on recent advances made in understanding HSP90 chaperone structure-function relationships, identification of new HSP90 client proteins and, more importantly, on the advancements of HSP90 targeted therapy based on various existing and emerging classical inhibitors.
Export Options
About this article
Cite this article as:
Haque Absarul, Alam Qamre, Zubair Alam Mohammad, I. Azhar Esam, Hussain Wali Sait Khalid, Anfinan Nisrin, Mushtaq Gohar, Amjad Kamal Mohammad and Rasool Mahmood, Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer, Current Pharmaceutical Design 2016; 22 (20) . https://dx.doi.org/10.2174/1381612822666160325152200
DOI https://dx.doi.org/10.2174/1381612822666160325152200 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanocellulose-based Delivery Systems and Cervical Cancer: Review of the Literature
Current Pharmaceutical Design Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Understanding the Molecular Mechanisms of Betel miRNAs on Human Health
MicroRNA SYNTHESIS AND APPLICATIONS OF Fe3O4/SiO2 CORE-SHELL MATERIALS
Current Pharmaceutical Design Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets The Balancing Act between Colonisers and Inflammation: T regulatory and TH17 Cells in Mucosal Immunity during Otitis Media
Current Immunology Reviews (Discontinued) Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Current Cancer Drug Targets In Search of Natural Remediation for Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Imaging of Cyclooxygenase-2 (COX-2) Expression: Potential Use in Diagnosis and Drug Evaluation
Current Pharmaceutical Design An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design In Silico Studies Most Employed in the Discovery of New Antimicrobial Agents
Current Medicinal Chemistry Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design Interaction and Cytotoxic Effects of Hydrophobized Chitosan Nanoparticles on MDA-MB-231, HeLa and Arpe-19 Cell Lines
Current Topics in Medicinal Chemistry Harnessing the Power of Cerenkov Luminescence Imaging for Gastroenterology: Cerenkov Luminescence Endoscopy
Current Medical Imaging Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets